<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The epithelial mucin MUC1 is overexpressed on the cell surface of many epithelial <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> as well as on some B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we identified two HLA-A2-restricted T-cell <z:chebi fb="0" ids="53000">epitopes</z:chebi> derived from the MUC1 protein </plain></SENT>
<SENT sid="2" pm="."><plain>To further extend the potential application of these <z:chebi fb="7" ids="16670">peptides</z:chebi>, we analyzed the expression of MUC1 on blast cells from patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 43) and several other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> including <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 24), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (n = 36), hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 9), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 7), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 12) </plain></SENT>
<SENT sid="3" pm="."><plain>Using reverse transcription-PCR and MUC1-specific monoclonal antibodies, MUC1 expression was found in 67% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples and 92% of <z:mp ids='MP_0009440'>myeloma</z:mp> samples </plain></SENT>
<SENT sid="4" pm="."><plain>To analyze the presentation of MUC1 <z:chebi fb="7" ids="16670">peptides</z:chebi> by primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts, we induced MUC1-specific CTLs in vitro using <z:chebi fb="7" ids="16670">peptide</z:chebi>-pulsed dendritic cells from HLA-A2+ healthy donors as antigen-presenting cells </plain></SENT>
<SENT sid="5" pm="."><plain>These CTLs efficiently lysed in an antigen-specific and HLA-A2-restricted manner not only target cells pulsed with the antigenic <z:chebi fb="7" ids="16670">peptide</z:chebi> but also <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines including <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> cells and primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts that constitutively expressed both MUC1 and HLA-A2 </plain></SENT>
<SENT sid="6" pm="."><plain>The specificity of the CTLs was confirmed in a cold target inhibition assay </plain></SENT>
<SENT sid="7" pm="."><plain>Our data demonstrate that MUC1-derived <z:chebi fb="7" ids="16670">peptides</z:chebi> are <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigens in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and several other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> that could potentially be used for immunotherapeutic approaches </plain></SENT>
</text></document>